This economic review highlights once again that, despite the majority of all patients treated for cancer receiving radiation therapy, Medicare expenditures across all radiation modalities is remarkably less than 2% of that spent on oncologic drugs, reminding us to advocate for fair reimbursement for our ever-evolving technology and the skill it requires. | DiGiaimo & Briggers, LinkedIn 2023
